XML 37 R25.htm IDEA: XBRL DOCUMENT v3.22.1
Segment Reporting
9 Months Ended
Mar. 31, 2022
Segment Reporting  
Segment Reporting

19. Segment Reporting

The Company’s chief operating decision maker (“CODM”), who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews

financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: BioPharma and Consumer Health. The BioPharma segment consists of the Company’s prescription products. The Consumer Health segment contains the Company’s consumer healthcare products.

Select financial information for these segments is as follows:

Three Months Ended

Nine Months Ended

March 31, 

March 31, 

    

2022

    

2021

2022

    

2021

(In thousands)

(In thousands)

Consolidated revenue:

  

 

  

  

 

  

BioPharma

$

13,862

$

5,127

$

42,388

$

18,091

Consumer Health

 

10,337

 

8,356

 

26,833

 

24,059

Consolidated revenue

$

24,199

$

13,483

$

69,221

$

42,150

Consolidated net loss:

 

  

 

  

 

  

 

  

BioPharma

$

(52,311)

$

(23,570)

$

(88,359)

$

(34,788)

Consumer Health

 

(762)

 

(1,890)

 

(4,113)

 

(4,503)

Consolidated net loss

$

(53,073)

$

(25,460)

$

(92,472)

$

(39,291)

March 31, 

June 30, 

2022

2021

(In thousands)

Total assets:

BioPharma

$

139,127

$

236,449

Consumer Health

 

29,699

 

29,219

Consolidated assets

$

168,826

$

265,668